A DECLARATION OF JOINT WORKING BETWEEN

Manchester University NHS Foundation Trust, hosting organisation for Health Innovation Manchester, Citylabs 1.0, Nelson Street, Manchester, M13 9NQ ("HinM")

and

AstraZeneca UK, 8th Floor, 2 Pancras Square, N1C 4AG ("AZ")

HinM and AZ are engaged in a joint working project:

'Access Spirometry Remotely (ASPIRE) in Greater Manchester'

Aims and Objectives

This joint working project aims to pilot the delivery of a remote spirometry service within Greater Manchester.

The main objective is to improve respiratory outcomes for patients in Greater Manchester, via the provision of a remote spirometry service, at a location best suited to the patients' needs. We hope to deliver this by:

- Providing remote spirometry in accurate and timely manner to support diagnosis of COPD or asthma that will allow health care professionals to provide optimal treatment based on the patients' clinical need and by following national and locality guideline and formulary.
- Identifying which patient cohorts are suitable/not suitable for remote spirometry.
- Provide a service that will not cost any more than current standard of care, nor have a negative impact on local NHS resources.
- Reviewing and suggesting patient pathway changes, to implement a remote spirometry service for appropriate patients, that would fit seamlessly alongside current standard of care and as an alternative to referral to specialist centres/care to offer a choice to patients and practices.
- Reduce health inequalities via engagement with communities who do not traditionally take up spirometry service offerings, to understand how we can make it as widely accessible as possible.
- Contribute to reducing the backlog of patients who are on the waiting list for spirometry.

Potential Benefits

Patient benefits

- It is expected that this joint working project will benefit patients by improving diagnosis for asthma and COPD aligned to Greater Manchester Medicines Management Group guidelines. Subsequently, this should result in better patient experience of healthcare, optimised treatment regimens for individual patient and improved patient outcomes.

NHS

- It is expected that NHS will benefit from resolving spirometry back log, the practices will better understand their patient population including their suitability for remote spirometry services as well as improving the diagnosis of respiratory conditions.
- The data collected and outcomes of this project will highlight any benefits to asthma or COPD patients and NHS services, as well as help NHS in making further decisions around wider implementation of this service.
- This project will help NHS Greater Manchester to support implementation of Greater Manchester Medicines Management Group guidelines for diagnostic criteria for COPD and asthma
- If the project is successful, the case for change will recommend remote spirometry service, as a commissioned service.
- A non-exclusive, non-sublicensable license to use the Arising IP, subject to any additional terms as agreed between the parties

AZ

- AZ will benefit from understanding of the size of patient population suitable/not suitable for remote spirometry, the unmet need and NHS capacity/circumstances.
- AZ manufacture and supply a range of medicines, that have a license to be used as part of a COPD or asthma treatment regime. AZ also conduct research and development studies. This project may increase the number of potential participants for new clinical trials.
- All data (other than patient data) and Intellectual Property generated by the Joint Working Project will be owned by AZ ("the Arising IP")

The project will run from October 2023 to December 2025.

The project involves pooling of skills, experience and resources as well as a balance of contributions from both parties.